Sanofi, Celgene to spend combined $20B on separate biopharma deals

Monday morning saw the announcement of two very expensive acquisitions in the biopharmaceutical industry: France’s Sanofi buying U.S. hemophilia drugmaker Bioverativ and Celgene spending $9 billion to buy the remaining 90 percent of cancer immunotherapy specialist Juno Therapeutics.

As summarized by Reuters, the two megadeals were driven by a need for big pharmaceutical companies to find high-value replacements for their own older treatments that are no longer selling as well. If they can’t make those products from within, the best option is to buy out another company which already has something valuable.

“It takes a long time to introduce technology that makes a significant difference, and in the interim CEOs are looking at any way to get their hands on product where they believe they can make a decent return,” said Chris Stirling, head of KPMG’s global life sciences practice. “They’ve got to be seen to be doing things, otherwise they really struggle to convince investors.”

2018 had already seen billion dollar deals in biopharma after just a few weeks, including another big purchase by Celgene, which agreed to buy privately owned Impact Biomedicines for as much as $7 billion.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup